AMLX

#1804
Amylyx Pharmaceuticals, Inc. - Common Stock
14.3 5 USD
+0.91%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
13.95
14.37
Range Annuel
4.71
18.61
Changement quotidien
+0.91%
Changement Mensuel
-8.19%
Evolution sur 6 mois
-2.18%
Changement Annuel
+188.73%
Clôture Précédente
14.2 2
Open
14.0 1
Low
13.9 5
High
14.3 7
Volume
666
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 1.6 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-7.9
ratio cours/chiffre d'affaires
—

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Nouvelles